Mr. Robert D. Tessarolo has been Chief Executive Officer and President at Cipher Pharmaceuticals US LLC and Cipher Pharmaceuticals Inc. since April 17, 2017. Mr. Tessarolo has 22 years of experience in the pharmaceutical industry spanning business strategy, general management and commercial operations roles across multiple countries and therapeutic areas. He has demonstrated expertise in leading pharmaceutical organizations through start-up opportunities and turnaround challenges and delivering rapid growth, expansion and value creation. Mr. Tessarolo served as Vice President of Sales & Marketing of Biovail Pharmaceuticals Canada. Mr. Tessarolo's responsibilities include all aspects of commercial business within Canada, including marketing strategy, market research and access, reviewing all divisional sales and operational planning and budgeting as well as new product planning for Biovail. His practical sales and marketing experience includes operational planning, budgeting and accountability for quarterly sales reviews and departmental objectives on a national basis. Under his leadership, Mr. Tessarolo established a Canadian business of over 140 employees and $190 million in revenues, leading his team through several new product launches and the successful integration of multiple company acquisitions, including Warner Chilcott, Forest Labs and Allergan. He joined Actavis in 2011 and led its launch of Actavis, plc's Canadian Specialty Pharmaceutical Division and served as its President and General Manager. Mr. Tessarolo served as Vice President and General Manager of Celgene Corporation, where he was responsible for leading their U.S. Inflammation & Immunology business. He held senior roles within the commercial business division of a major Canadian based pharmaceutical company. He has been a Director of Cipher Pharmaceuticals Inc. since May 11, 2017. Mr. Tessarolo has been a Director of Bradmer Pharmaceuticals Inc., since March 11, 2008. He contributed to the substantial expansion of the U.S. business in 2016, which was led by the rapid growth of Otezla for plaque psoriasis and psoriatic arthritis. He is a graduate of Carleton University with a B.A in Economics. He has attended the Advanced Management Program for General Management at Ross School of Business at the University of Michigan.

 Inflammation & Immunology, Business Development, Economics